{"version":"1.0","provider_name":"South Africa Voice","provider_url":"https:\/\/southafricavoice.com","author_name":"South Africa Voice","author_url":"https:\/\/southafricavoice.com\/author\/southafricavoice01\/","title":"Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD) - South Africa Voice","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"7xF0aPuQTo\"><a href=\"https:\/\/southafricavoice.com\/zenas-biopharma-announces-first-patient-dosed-in-phase-3-clinical-study-of-obexelimab-for-the-treatment-of-immunoglobulin-g4-related-disease-igg4-rd\/\">Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/southafricavoice.com\/zenas-biopharma-announces-first-patient-dosed-in-phase-3-clinical-study-of-obexelimab-for-the-treatment-of-immunoglobulin-g4-related-disease-igg4-rd\/embed\/#?secret=7xF0aPuQTo\" width=\"600\" height=\"338\" title=\"&#8220;Zenas BioPharma Announces First Patient Dosed in Phase 3 Clinical Study of Obexelimab for the Treatment of Immunoglobulin G4-Related Disease (IgG4-RD)&#8221; &#8212; South Africa Voice\" data-secret=\"7xF0aPuQTo\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"Global Phase 3 INDIGO study will evaluate the efficacy and safety of obexelimab in patients with IgG4-RD, a chronic and serious fibroinflammatory disease typically affecting multiple organs IgG4-RD is the first of several potential disease indications to be pursued for obexelimab given its unique non-depleting, B-cell inhibition WALTHAM, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) \u2014 [\u2026]","thumbnail_url":"https:\/\/ci4.googleusercontent.com\/proxy\/u59vDKj76deBVVtEfu4DfgHUUNXr57ExL35-cViS4kBdLRXF0YNCelwtyHgjQPPjQJwc3yGyNMftvpzrV31lrrnPc6mFNojbUWtDnrSQRMTNE964nrrmKNHxvhXVsWcgTpuA3B_9IrAUbGzFJ1uHaP-UyV5TWBzy4A0V1d2YuMsJDAKvHQt34f4wSMSUkWfq8BLnYw=s0-d-e1-ft#https:\/\/ml.globenewswire.com\/media\/MWU4NTM1NjMtZjZiOS00YjdhLTlhMjktODI0OTBhZmZmMTUyLTEyMTkzNDg=\/tiny\/Zenas-BioPharma-USA-LLC.png"}